DK3810201T3 - GIP/GLP1-agonist-sammensætninger - Google Patents

GIP/GLP1-agonist-sammensætninger Download PDF

Info

Publication number
DK3810201T3
DK3810201T3 DK19739766.4T DK19739766T DK3810201T3 DK 3810201 T3 DK3810201 T3 DK 3810201T3 DK 19739766 T DK19739766 T DK 19739766T DK 3810201 T3 DK3810201 T3 DK 3810201T3
Authority
DK
Denmark
Prior art keywords
gip
agonist compositions
glp1 agonist
glp1
compositions
Prior art date
Application number
DK19739766.4T
Other languages
English (en)
Other versions
DK3810201T5 (da
Inventor
Vincent John Corvari
Christopher Sears Minie
Dinesh Shyandeo Mishra
Ken Kangyi Qian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67263049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3810201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK3810201T3 publication Critical patent/DK3810201T3/da
Application granted granted Critical
Publication of DK3810201T5 publication Critical patent/DK3810201T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19739766.4T 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger DK3810201T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688632P 2018-06-22 2018-06-22
PCT/US2019/037146 WO2019245893A2 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions

Publications (2)

Publication Number Publication Date
DK3810201T3 true DK3810201T3 (da) 2023-06-26
DK3810201T5 DK3810201T5 (da) 2023-08-21

Family

ID=67263049

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19739766.4T DK3810201T5 (da) 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger

Country Status (34)

Country Link
US (6) US11357820B2 (da)
EP (3) EP4785959A2 (da)
JP (4) JP6896945B2 (da)
KR (4) KR20250090374A (da)
CN (3) CN112312926A (da)
AR (1) AR115542A1 (da)
AU (3) AU2019289110B2 (da)
BR (1) BR112020023452A2 (da)
CA (1) CA3103469C (da)
CL (1) CL2020003359A1 (da)
CR (1) CR20200634A (da)
DK (1) DK3810201T5 (da)
EA (1) EA202092713A1 (da)
EC (1) ECSP20082717A (da)
ES (1) ES2953740T3 (da)
FI (1) FI3810201T3 (da)
HR (1) HRP20230748T1 (da)
HU (1) HUE063059T2 (da)
IL (2) IL295433B2 (da)
JO (1) JOP20200335B1 (da)
LT (1) LT3810201T (da)
MA (1) MA52965B1 (da)
MD (1) MD3810201T2 (da)
MX (2) MX2020013727A (da)
PE (2) PE20210049A1 (da)
PH (1) PH12020552215A1 (da)
PL (1) PL3810201T3 (da)
PT (1) PT3810201T (da)
RS (1) RS64288B9 (da)
SG (1) SG11202012744UA (da)
SI (1) SI3810201T1 (da)
TW (1) TWI705820B (da)
WO (1) WO2019245893A2 (da)
ZA (1) ZA202007162B (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
AU2019309798A1 (en) 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
KR20250044806A (ko) * 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
TW202228762A (zh) 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TW202423476A (zh) 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CN117866050A (zh) * 2021-05-28 2024-04-12 广东众生睿创生物科技有限公司 多肽的制备及其应用
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
WO2023131325A1 (zh) * 2022-01-10 2023-07-13 江苏豪森药业集团有限公司 一种稳定的受体激动剂的药物组合物、制备方法及其应用
KR20240136386A (ko) * 2022-01-18 2024-09-13 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애 치료를 위한 약학 제제 및 방법
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
WO2024006662A1 (en) * 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
JP2025523981A (ja) * 2022-07-20 2025-07-25 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための医薬製剤及び方法
AU2023347007A1 (en) * 2022-09-23 2025-05-08 Brightgene Bio-Medical Technology Co., Ltd. Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
WO2024086601A2 (en) * 2022-10-19 2024-04-25 Eli Lilly And Company Preserved gip/glp agonist compositions
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
WO2024192219A1 (en) * 2023-03-15 2024-09-19 Viking Therapeutics, Inc. Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4714434A1 (en) * 2023-05-19 2026-03-25 Aulbio Co., Ltd. Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same
EP4721729A1 (en) * 2023-06-02 2026-04-08 G2GBIO, Inc. Sustained-release microsphere preparation comprising tirzepatide or pharmaceutically acceptable salt thereof and method for preparing same
WO2025087344A1 (en) * 2023-10-25 2025-05-01 Beta Pharma, Inc. Glp1-r/gipr dual peptide agonists and use thereof
WO2025141472A1 (en) * 2023-12-27 2025-07-03 Alembic Pharmaceuticals Limited Stable pharmaceutical compositions comprising tirzepatide
WO2025191149A1 (en) 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
CN120829494A (zh) * 2024-04-18 2025-10-24 苏州星曜坤泽生物制药有限公司 一种glp-1gip类似物、fgf21蛋白、三功能蛋白及其应用
EP4656183A1 (en) 2024-05-31 2025-12-03 Galenicum Health SLU Tirzepatide compositions and preparation method
WO2026013454A1 (en) 2024-07-11 2026-01-15 Orbicular Pharmaceutical Technologies Pvt. Ltd. Multi-dose pen of tirzepatide
WO2026059846A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company Dissolving microneedle patch for transdermal delivery of a peptide
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device
US12623022B1 (en) 2025-02-26 2026-05-12 Genzyme Corporation Medicament delivery device
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12691229B1 (en) 2025-02-26 2026-07-28 Genzyme Corporation Medicament delivery device
US12539367B1 (en) 2025-02-26 2026-02-03 Genzyme Corporation Medicament delivery device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
ES2288018T3 (es) * 1998-04-03 2007-12-16 Novartis Vaccines And Diagnostics, Inc. Formulaciones inyectables de igf que contienen succinato como tampon.
DE60137876D1 (de) 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
ES2575984T3 (es) 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
JP2008525452A (ja) 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
JP2009501200A (ja) * 2005-07-12 2009-01-15 レノボ・リミテッド ＴＧＦ−βスーパーファミリーメンバーを含有する医薬組成物
RU2409349C2 (ru) * 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
KR20100020516A (ko) 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1-ｆｃ 융합 단백질 제제
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
DK2708252T3 (da) 2010-03-01 2015-11-02 Lilly Co Eli Automatisk injektionsanordning med forsinkelsesmekanisme indbefattende dobbeltfungerende forspændingselement
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
HUE049152T2 (hu) 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN103893744B (zh) 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
JP2016522241A (ja) 2013-06-21 2016-07-28 ノヴォ ノルディスク アー／エス インスリンで治療された及び／又は１型糖尿病に罹患している患者におけるｇｌｐ−１受容体作動薬の新規の使用
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
AR103242A1 (es) 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
KR20240037175A (ko) * 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
US12453755B2 (en) 2025-10-28
US20260053888A1 (en) 2026-02-26
CN119424616A (zh) 2025-02-14
US12453756B2 (en) 2025-10-28
PH12020552215A1 (en) 2021-06-28
ZA202007162B (en) 2025-05-28
TWI705820B (zh) 2020-10-01
CN119424616B (zh) 2025-11-07
HUE063059T2 (hu) 2023-12-28
IL295433B1 (en) 2023-11-01
HRP20230748T1 (hr) 2023-10-27
AU2024266715A1 (en) 2024-12-19
US11918623B2 (en) 2024-03-05
ECSP20082717A (es) 2021-01-29
IL279504B (en) 2022-09-01
EA202092713A1 (ru) 2021-04-05
MX2025004309A (es) 2025-05-02
NZ770042A (en) 2024-07-26
IL279504A (en) 2021-01-31
JOP20200335A1 (ar) 2020-12-20
PL3810201T3 (pl) 2023-09-25
JP7700205B2 (ja) 2025-06-30
EP4257185A3 (en) 2024-01-17
JP2021167314A (ja) 2021-10-21
WO2019245893A2 (en) 2019-12-26
JP2025102837A (ja) 2025-07-08
TW202015717A (zh) 2020-05-01
LT3810201T (lt) 2023-07-25
US11357820B2 (en) 2022-06-14
MD3810201T2 (ro) 2023-11-30
PT3810201T (pt) 2023-07-04
KR20230058172A (ko) 2023-05-02
IL295433A (en) 2022-10-01
US12629404B2 (en) 2026-05-19
SG11202012744UA (en) 2021-01-28
CA3103469A1 (en) 2019-12-26
JP6896945B2 (ja) 2021-06-30
KR102523489B1 (ko) 2023-04-21
US20240226229A1 (en) 2024-07-11
AU2019289110B2 (en) 2022-10-06
JP7863651B2 (ja) 2026-05-21
AU2024266715B2 (en) 2026-08-13
US20250367253A1 (en) 2025-12-04
EP4785959A2 (en) 2026-08-05
CN112312926A (zh) 2021-02-02
CN119424615A (zh) 2025-02-14
MA52965B1 (fr) 2023-08-31
AR115542A1 (es) 2021-01-27
FI3810201T3 (fi) 2023-08-17
CR20200634A (es) 2021-01-21
EP4257185A2 (en) 2023-10-11
PE20210049A1 (es) 2021-01-08
EP3810201A2 (en) 2021-04-28
IL295433B2 (en) 2024-03-01
JP7413315B2 (ja) 2024-01-15
KR20210010572A (ko) 2021-01-27
KR20240060873A (ko) 2024-05-08
US20190388502A1 (en) 2019-12-26
AU2019289110A1 (en) 2021-01-21
JOP20200335B1 (ar) 2024-04-18
MX2020013727A (es) 2021-03-02
ES2953740T3 (es) 2023-11-15
US20250186544A1 (en) 2025-06-12
AU2022279524A1 (en) 2023-02-02
WO2019245893A3 (en) 2020-03-12
EP3810201B9 (en) 2023-08-02
MA52965A (fr) 2021-04-28
EP4257185B1 (en) 2026-08-05
SI3810201T1 (sl) 2023-08-31
PE20242299A1 (es) 2024-12-11
JP2021506952A (ja) 2021-02-22
EP3810201B1 (en) 2023-06-07
BR112020023452A2 (pt) 2021-02-23
KR20250090374A (ko) 2025-06-19
DK3810201T5 (da) 2023-08-21
JP2024041808A (ja) 2024-03-27
RS64288B1 (sr) 2023-07-31
CL2020003359A1 (es) 2021-06-25
CA3103469C (en) 2024-04-09
RS64288B9 (sr) 2023-11-30
US20220273762A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
DK3810201T5 (da) GIP/GLP1-agonist-sammensætninger
IL279827A (en) Gip/glp1 co-agonist compounds
IL283692A (en) Novel composition
EP3849598A4 (en) ANTI-TREM-2 AGONIST ANTIBODIES
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP3823584A4 (en) DETERGENT COMPOSITION
EP3853332C0 (en) COMPOSITION
DK3924443T3 (da) Compositions
EP3882323A4 (en) COMPOSITION
DK3840596T3 (da) Sammensætning
EP3871694A4 (en) COMPOSITION
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
EP3812426A4 (en) CURABLE COMPOSITION
DK3746054T3 (da) Sammensætninger omfattende berberin
DK3808747T3 (da) Imidazopyridinon-forbindelse
EP3981256A4 (en) COMPOSITION
EP3954721A4 (en) Composition
EP3941942A4 (en) COMPOSITION
PT3765379T (pt) Composições
EP3914303C0 (en) VIRUCIDAL COMPOSITION
EP3741814C0 (en) COMPOSITION
EP3875451A4 (en) TLR8 AGONIST
EP3829532A4 (en) KERATIN COMPOSITIONS
EP3821574C0 (en) Digital isolator
EP3900790A4 (en) COMPOSITION